Showing posts with label medicaid fraud control unit. Show all posts
Showing posts with label medicaid fraud control unit. Show all posts

Thursday, December 12, 2019

DOJ: Bill Barr Addresses The National Association of Attorneys General 2019 Capital Forum - No Mention Of Medicaid Fraud In Child Welfare Or Parental Rights

Boo Boo Barr!

But, what about Medicaid Fraud in Child Welfare?

What about the States Attorneys General Medicaid Fraud Control Units?

How about addressing Parental Rights, and not just corporate parental rights of foreign corporations?

We need to talk...

Remember this?

Michigan Medicaid Fraud To Be Discussed In Appropriations


I was watching this youtuber who goes by the name of John Oloughlin who mentioned that you were Opus Dei.

I figured that the only way he knew this was because he was also Opus Dei.

He went to the Red Mass of the John Caroll Society of the Archdiocese of Washington.

My Sweetie never went to that Mass.

https://web.archive.org/web/20151214055757/http://www.johncarrollsociety.org/jcs-membership/the-red-mass/index.aspx

This is about the U.S. Conference of Catholic Bishops operating as a foreign corporation.

The Tale Of Burisma, Hunter Biden, Taggart Romney, Their Daddies, Deutsche Bank & Trafficking Tiny Human Trust Funds With Catholic Charities







The Cathedral of St. Nicholas is glorious in Kiev and seems to have a strong presence in Michigan.

https://opusdei.org/uk-ua/

I just thought I would share.

I like to share.

Would you like me to share some more stuff?

Very well.....stop stealin' the children, land & votes.





  • WashingtonDC
     ~
    Tuesday, December 10, 2019

    Remarks as Prepared for Delivery
    Good afternoon.  Thank you General Landry for that kind introduction, and thank you to the National Association of Attorneys General (NAAG) for inviting me to join you today.  It is an honor and privilege to be here with my fellow attorneys general.
    Through the Executive Working Group and in various operations, we are working together on several important law enforcement priorities.  Elder Justice is a personal priority for me, and I know the State AGs have been leading the charge for many years.  Derrick Schmidt’s Presidential initiative highlighted the impact of this important issue.  Each year, over three billion dollars are stolen or defrauded from millions of America’s elderly through a variety of malicious scams.  The State AGs are on the front line in this fight to protect the elderly from being exploited, and I pledge the Department’s full support in that effort.     
    Similarly, human trafficking is an extremely important law enforcement issue for both the DOJ and the States AGs.  Attorneys General Paxton, Healey, Bacerra, Reyes and many others have been leaders in this vital effort.  We worked together to take down backpage.com, and we continue to engage our state partners though our Human Trafficking Prosecutorial Unit.  We look forward to continuing that work with you to make more progress in the year ahead.  
    In addition to these important priorities, another topic that involves almost every AG in this room and one that also benefits from close federal-state cooperation is the review into market-leading online platforms. 
    I. Benefits of Broad State AG Support on Review of Market-Leading Online Platforms
    In DC, it’s hard to find many things that everyone agrees on.  One thing that has found wide and bi-partisan support, however, is the government taking a closer look at the leading online platforms and the competitiveness of digital markets.
    Online platforms play an important role in our economy and in Americans’ daily lives, often serving as gateways for how we access goods, services, information and even each other. 
    A few digital platforms in particular have enjoyed significant growth over the past decade.  Consumers now depend on these platforms every day.  Their size and pervasiveness have led to public concerns about the competitive health of these digital markets. 
    We’ve heard widespread concerns from consumers, businesses and entrepreneurs, including about stagnated innovation, high prices, lack of choice, privacy, transparency, and public safety.  In response, DOJ initiated a review into market-leading online platforms, which we announced publicly last July. 
    Concerns about online platforms have come from a wide variety of stakeholders, across the political spectrum.  Indeed, almost every State AG is now participating in publicly announced antitrust investigations of Google and Facebook.  I’ve had the benefit of meeting with representatives of these groups at the Department, and believe we have a good cooperative relationship in these efforts.
    This is not the first time that the Department of Justice has cooperated with a bi-partisan coalition of State AGs on an antitrust matter involving a digital platform.
    When the Department of Justice litigated a case against Microsoft roughly 20 years ago for antitrust violations, it was joined by a coalition of 20 state attorneys general and the District of Columbia.  There are still those in the Department and State AG community, including my friend Tom Miller, who were closely involved and remember it well.
    Today, the State AG coalitions investigating Google and Facebook are even bigger than in Microsoft, including almost every state and federal territory.  I think this demonstrates the importance of these issues to Americans across the country, regardless of location or political persuasion.
    II. Benefits of a Broad, Holistic Perspective
    The benefits of a broad approach to online platforms go beyond building a federal-state partnership.  A broader, holistic perspective is also important as we consider substantive issues raised by the digital economy, both within and outside of the arena of antitrust.
    Let me start with antitrust.  Antitrust is a core focus of the Department’s review into market-leading platforms because, ultimately, fair competition can cure many of the ills we see.  In a functioning free market, consumers can demand alternatives that better address their preferences, including for greater privacy, more transparency, or increased safety.  For consumer choice and the free market to work, however, firms have to be playing by the established rules of competition. That’s where antitrust enforcement steps in.
    Many online platforms are not only big, but also offer a wide breadth of products and services.  Antitrust enforcers therefore must take an equally broad view of these platforms’ offerings, and the relationships between different markets, products, and business practices.
    Let me touch on a few examples of where a broader perspective is useful in an antitrust analysis.
    First, a broader perspective requires understanding the characteristics of the market.  This includes looking at whether there are high barriers to entry that prevent or deter new competitors.  For example, digital platform markets are often characterized by economies of scale and scope, including direct and indirect network effects. 
    Take, for example, direct network effects in social media.  The more users on the same social media platform, the more valuable that platform is overall.  There are benefits to consumers from being on the same network as their friends and family.  At the same time, the existence of such network effects can make it harder for a new platform to attract users.  
    This positive feedback loop is also inherent in platforms that rely on data and machine-learning.  For example, generally speaking, the more data a search engine has, the better its algorithms for search results can be.  The better the algorithm, the more users it can attract, and with them comes even more data.  And the cycle starts anew. 
    Digital platforms can also have indirect network effects, meaning the more users on one side of the platform increases the value to users on the other side of the platform. 
    In Microsoft, for example, there were indirect network effects that created what the court described as an “applications barrier to entry.”  The more consumers that used the Microsoft operating system, the more attractive the platform was to application developers.  Conversely, the more applications that were on the Microsoft operating system, the more attractive the platform was for users.  These indirect network effects created a barrier to entry that helped protect Microsoft’s monopoly. 
    Network effects are not inherently problematic.  However, where strong network effects create a significant barrier to entry, it can lead to increased market power, which in turn can be used in anticompetitive ways.  
    Given these dynamics, antitrust enforcers must be particularly vigilant to police for agreements and conduct that harm the competitive process.
    Similarly, market power is not itself wrongful.  As I’ve said before, big is not necessarily bad.  Healthy competition creates winners and losers, and the prospect of winning (and the profits that come with it) can drive innovation in the first place.  Success that comes from creating a better, more innovative product should be applauded.  The danger, however, is that a monopolist (even one who earned that status lawfully) can be tempted to use their power to engage in anticompetitive conduct to preserve their dominant position. 
    Moreover, the existence of market power can change the competitive effects of a business practice.  Conduct that may be procompetitive for a new entrant can become anticompetitive if undertaken by the incumbent 800 pound gorilla.  
    For example, exclusivity agreements by a new entrant can increase competition by enabling a competitor to attract users with unique offerings, even in markets with strong network effects.  At the same time, exclusive dealing by a monopolist could have the opposite effect by depriving rivals of the inputs or scale necessary to compete. 
    Bundling, tying, predatory pricing, and certain refusals to deal are other examples of conduct that can become problematic when undertaken by a firm with market or monopoly power. 
    As digital firms transition from being the disruptive new entrant into an established market leader, they should pay attention to the impact of their business practices.  So too should the antitrust enforcers.
    Second, in addition to understanding the dynamics within a market, like barriers to entry and market power, we also need to look at relationships between markets.  This is especially important because today’s digital platforms frequently operate across multiple areas.  
    A dominant firm may seek to leverage its monopoly power in one market to gain an unfair advantage in another.  In the Microsoft case, for example, a key concern was that Microsoft was abusing its dominant position in operating systems to foreclose competition in browsers. 
    The relationships between markets can be even more complex in the digital age, with the emergence of new business models and an increasingly important role of data.  Law enforcers need to better understand how consumer data is collected, used, and shared within a firm and with third parties.  Such antitrust inquiries generally require a broader perspective and deeper understanding of how each of these markets function.
    Third, taking a broader perspective is particularly important in the context of “free” online services.  Digital platforms are not charities.  When they offer services to consumers for “free,” that just means they are making money somewhere else, either through a different product, from different consumers, or at a different point in time. 
    The increasing prevalence and complexity of “free” digital services may require a broader perspective.
    For example, antitrust enforcers may need to look beyond the free service to better understand a firm’s monetization strategy and incentives.  Enforcers also may need to look more closely at non-price effects.  Fortunately, the long-standing consumer welfare standard enables us to analyze non-price effects on competition, including on quality, innovation, and consumer choice. 
    A broader perspective also requires looking beyond antitrust.  As we listen to complaints from the public, industry, and experts, it has become clear that not every problem related to online platforms comes within the reach of antitrust law. 
    Some have therefore proposed expanding the antitrust laws to reach other non-economic harms.  Drastically re-inventing the antitrust laws, however, is neither easy nor advisable.  The Sherman Act has been around for over a century and has proved flexible enough to adapt to a wide variety of industries, including digital platforms.  We are open to considering new tools and targeted modifications, but a wholesale departure from the antitrust laws’ focus on competition is unwarranted.
    While we should not distort the antitrust laws, the Department of Justice also cannot ignore real harms to the American people.  Where there are non-competition harms, the Department will consider whether there are other tools – including other legal or policy frameworks – that can help.  We are thinking critically about how the Department, and our state and federal partners, can address other topics related to online platforms, such as privacy, transparency, consumer fraud, child exploitation, or public safety.
    One example of a non-antitrust issue related to online platforms is Section 230 of the Communications Decency Act.  Generally speaking, Section 230 provides immunity to interactive computer services for third-party content on their platforms. 
    As this group well knows, there is currently a robust public debate over Section 230.  The NAAG sent a letter to Congress last May, proposing an amendment that would carve out U.S. state and territorial criminal law from the current scope of Section 230 immunity.  We, too, are studying Section 230 and its scope. 
    The CDA was passed in 1996 in response to concerns about protecting children from sexually explicit content on the internet.  Section 230 was enacted primarily for two purposes.
    The primary purpose of the amendment was to encourage platforms to self-regulate by granting immunity for blocking or filtering offensive material.  In particular, the amendment aimed to overrule a 1995 state court decision that treated an online message board as a publisher of third-party content, and thus liable for defamation, because the service restricted access to some, but not other, objectionable material.
    Another purpose was to encourage the growth of online forums by immunizing platforms against liability for third party speech.  Section 230 was passed at a time where the internet was relatively new, and Congress wanted to protect the growth of online services and the ability for the internet to offer “a forum for true diversity of political discourse.” 
    Section 230 has been interpreted quite broadly by the courts.  Today, many are concerned that Section 230 immunity has been extended far beyond what Congress originally intended.  Ironically, Section 230 has enabled platforms to absolve themselves completely of responsibility for policing their platforms, while blocking or removing third-party speech – including political speech – selectively, and with impunity. 
    Some also question whether such a broad immunity is still necessary to protect online companies.  Indeed, ten years ago, a Ninth Circuit opinion denying Section 230 immunity in part remarked: “The Internet is no longer a fragile new means of communication that could easily be smothered in the cradle by overzealous enforcement of laws and regulations applicable to brick-and-mortar businesses.”  Fair Housing Council of San Fernando Valley v. Roommates.com LLC, 521 F.3d 1157, 1164 n. 15 (9th Cir. 2008).  In other words, the opinion stated:  “the Internet has outgrown its swaddling clothes and no longer needs to be so gently coddled.”  Id. at 1175, n. 39.
    The staggering breadth of Section 230 immunity, as construed by the courts, is evident in a recent Second Circuit opinion involving the Anti-Terrorism Act.  See Force v. Facebook, Inc., 934 F.3d 53 (2nd Cir. 2019).  There, the court held that Facebook was immune under Section 230 for allegedly matching and facilitating communications between members of the terrorist group Hamas.  The court denied plaintiff’s argument that Facebook’s algorithms and friend-matching service rendered it a “non-publisher” outside the scope of Section 230.  Id. at 66.
    Chief Judge Katzmann dissented in part, criticizing the virtually limitless scope of Section 230 immunity imposed by some courts.  He argued that providing immunity for the steps Facebook took to connect alleged terrorists through algorithm and friend suggestions was far removed from the original purpose of the CDA to protect children against obscene material online.  He called for Congress to revisit the CDA to “better calibrate the circumstances where such immunization is appropriate and inappropriate in light of congressional purposes.”  Id. at 77.
    Chief Judge Katzmann is not alone in his calls for reform.  Section 230 has garnered significant attention from experts, consumer groups, and legislators.  Within DOJ, we also have started thinking critically this issue. 
    The purpose of Section 230 was to protect the “good Samaritan” interactive computer service that takes affirmative steps to police its own platform for unlawful or harmful content.  Granting broad immunity to platforms that take no efforts to mitigate unlawful behavior or, worse, that purposefully blind themselves — and law enforcers — to illegal conduct occurring on, or facilitated by, the online spaces they create, is not consistent with that purpose. 
    We want to engage further with experts, industry, and other government actors, including the NAAG, through informal discussions as well as a public workshop.
    III. Coordination is Key
    As we look at Section 230, antitrust, and other issues raised by the online platforms, it is important to take a coordinated approach. 
    The issues raised by online platforms are interrelated, and we sometimes must weigh competing interests in forming positions related to the digital economy. 
    Privacy is a good example.  Overbroad and overly burdensome privacy legislation could inhibit competition by entrenching monopolists with the resources to comply, while thwarting newer entrants who do not have those resources.
    A single-minded focus on privacy, above all other values, also can impose significant costs, including costs to public safety.  I have, for example, spoken before about the dangers of warrant-proof encryption.  I won’t repeat myself here, but would simply reiterate that technological innovations that purport to protect privacy at all costs – while impeding sworn law enforcers’ ability to go after violent criminals, child predators, human traffickers, and terrorists, even once the enforcers satisfied the rigorous privacy protections built into the Fourth Amendment — may not be worth the trade-off.
    High level coordination in our review of market-leading online platforms also helps avoid imposing conflicting obligations or inconsistent policy positions.  This requires coordination both within and outside DOJ. 
    While we have some of the best and brightest at the DOJ’s Antitrust Division and across the Department working on these issues, we benefit from the perspective and support of our State AG, federal, and international partners.  We are also welcoming consumers, businesses, experts, and others to talk and work with us to address the challenges of the digital age.
    ***
    The technology industry in America has brought great innovations to consumers in the US and around the world.  We must continue to encourage and incentivize innovation and economic growth.  This means not unfairly punishing innovators that have earned their success on the merits.  But it also means making sure markets are competitive and open to the next wave of technological change. 
    As law enforcers, we also must keep up with technological advancements to best protect our citizens.  This is why we have made the review of market-leading online platforms a top priority of the Department. 
    The State AG community plays a very important role in this endeavor.  On behalf of DOJ, I thank you all for your valuable partnership and look forward to our continued work together on this and many other initiatives.

    Voting is beautiful, be beautiful ~ vote.©

    Thursday, October 10, 2019

    Time To Address How Justice Is Dispensed To Foster Children - Not One Penny Of $8 Billion Risperdal Settlement Will Go To Medicaid Billed Foster Kids Who Were Lab Rats

    FUN FACT! REISPERDAL WAS TESTED ON FOSTER KIDS AS LAB RATS

    ANOTHER FUN FACT! WHEN FOSTER BOYS WOULD GROW BREASTS, THEY WERE PRESCRIBED MORE SECOND GENERATION ANTIPSYCHOTROPICS TO STOP THE BREAST GROWTH

    Just think.

    Arnold & Itkin LLP
    Arnold & Itkin
    Not one foster boy who was used as a lab rat and grew breasts will receive one red penny.

    Not a dime.

    Not even allowed access to their medical records upon aging out or escaping of foster care to a life on the streets, with breasts.

    Why, you may ask?

    Because no one cares and the attorneys will get the largest chunk of the damages, with the States in tow, launching more foreign Social Impact Bond programs, for more socioeconomic experiments, to their Public Private Partnerships, to fund campaigns.

    I called Arnold & Itkin to ask if any foster kids would receive part of the settlement, or if the firm is going to work with the States Medicaid Fraud Control Units, but was told that the settlement was for their client.

    One person, where not one penny goes to the Foster Kids who were used as lab rats, where the illegal use of Risperdal was billed to Medicaid, where not one penny will be reimbursed to the States.

    The law firm did take my information and said they would call me back.

    They asked with whom I was working.

    I informed them that I would be reporting to the U.S. Department of Justice, who can then refer to the proper conjugal collaboration, just as soon as I publish.

    Oh, and if a parent lodges a formal complaint, they are met with threats of termination of parental rights, to put the boy up for adoption to be sold, and continue being drugged above and beyond adult dosages.

    Will the States Medicaid Fraud Control Units do anything?

    Utah Attorney General Mark Schurtleff did, where his original complaint is below, but it seemed to get rather murky, and it seems to be ongoing.

    Everything you wanted to know about Risperdal and foster kids if here.

    Here is everything you wanted to know about drugging foster kids as lab rats - antipsychotropic experiments.

    It is time to address how justice is dispensed to Foster Children.

    Just keeping it real.

    Johnson & Johnson to pay $8B in damages for Risperdal drug linked to female breast tissue in boys

    Johnson & Johnson to pay $8B in damages for Risperdal drug linked to female breast tissue in boys

    A Philadelphia jury on Tuesday awarded $8 billion in punitive damages against Johnson & Johnson and one if its subsidiaries over a drug the companies made that the plaintiff's attorneys say is linked to the abnormal growth of female breast tissue in boys.

    Image result for johnson and johnson
    Risperdal
    PHILADELPHIA (AP) - A Philadelphia jury on Tuesday awarded $8 billion in punitive damages against Johnson & Johnson and one if its subsidiaries over a drug the companies made that the plaintiff's attorneys say is linked to the abnormal growth of female breast tissue in boys.

    Johnson and Johnson immediately denounced the award after the jury's decision in the Court of Common pleas, saying it's "excessive and unfounded" and vowing immediate action to overturn it.

    The antipsychotic drug Risperdal is at the center of the lawsuit, with the plaintiff's attorneys arguing it's linked to abnormal growth of female breast tissue in boys, an incurable condition known as gynecomastia.

    Johnson & Johnson used an organized scheme to make billions of dollars while illegally marketing and promoting the drug, attorneys Tom Kline and Jason Itkin said in a statement.

    Johnson & Johnson said in a statement on its website it was confident that the award would be overturned, calling it "grossly disproportionate" with the initial compensatory damage award and "a clear violation of due process."

    Johnson & Johnson said the court's exclusion of key evidence left it unable to present a meaningful defense, including what they said was a drug label that "clearly and appropriately outlined the risks associated with the medicine" or Risperdal's benefits for patients with serious mental illness. They also said the plaintiff's attorneys failed to present any evidence of actual harm.

    "This decision is inconsistent with multiple determinations outside of Philadelphia regarding the adequacy of the Risperdal labeling, the medicine's efficacy, and findings in support of the company," Johnson & Johnson said. "We will be immediately moving to set aside this excessive and unfounded verdict."

    Utah AG Attacks Medicaid Fraud


    Voting is beautiful, be beautiful ~ vote.©

    Thursday, July 11, 2019

    DOJ: $1.4 Billion Conjugal Collabortive With The Virginia Medicaid Fraud Control Unit

    “This historic resolution is the product of a continued partnership with the Virginia Medicaid Fraud Control Unit, FDA, HHS, and the U.S. Postal Service.”
    First Assistant United States Attorney Daniel P. Bubar of the Western District of Virginia

    49 more States Medicaid Fraud Control Units to go!

    Justice Department Obtains $1.4 Billion from Reckitt Benckiser Group in Largest Recovery in a Case Concerning an Opioid Drug in United States History

    Global consumer goods conglomerate Reckitt Benckiser Group plc (RB Group) has agreed to pay $1.4 billion to resolve its potential criminal and civil liability related to a federal investigation of the marketing of the opioid addiction treatment drug Suboxone. The resolution – the largest recovery by the United States in a case concerning an opioid drug – includes the forfeiture of proceeds totaling $647 million, civil settlements with the federal government and the states totaling $700 million, and an administrative resolution with the Federal Trade Commission for $50 million.
    Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. Suboxone and its active ingredient, buprenorphine, are powerful and addictive opioids. 
    “The opioid epidemic continues to be a serious crisis for our nation, and I’m proud of the work the Department of Justice and our partners are doing to address this epidemic,” said Principal Deputy Associate Attorney General Claire Murray.
     “We are confronting the deadliest drug crisis in our nation’s history. Opioid withdrawal is difficult, painful, and sometimes dangerous; people struggling to overcome addiction face challenges that can often seem insurmountable,” said Assistant Attorney General Jody Hunt for the Department of Justice’s Civil Division. “Drug manufacturers marketing products to help opioid addicts are expected to do so honestly and responsibly.”
    Resolution of the Criminal Investigation
    Until December 2014, RB Group’s wholly owned subsidiary, Indivior Inc. (then known as Reckitt Benckiser Pharmaceuticals Inc.) marketed and sold Suboxone throughout the United States. In December 2014, RB Group spun off Indivior Inc., and the two companies are no longer affiliated. On April 9, a federal grand jury sitting in Abingdon, Virginia, indicted Indivior for allegedly engaging in an illicit nationwide scheme to increase prescriptions of Suboxone. The United States’ criminal trial against Indivior is scheduled to begin on May 11, 2020, in the United States District Court in Abingdon, Virginia. Indivior is presumed innocent until proven guilty.
    To resolve its potential criminal liability stemming from the conduct alleged in the indictment of Indivior, RB Group has executed a non-prosecution agreement that requires the company to forfeit $647 million of proceeds it received from Indivior and not to manufacture, market, or sell Schedule I, II, or III controlled substances in the United States for three years. In addition, RB Group has agreed to cooperate fully with all investigations and prosecutions by the Department of Justice related, in any way, to Suboxone.
    “Today’s announcement demonstrates that this office will work tirelessly to address all facets of the opioid epidemic,” First Assistant United States Attorney Daniel P. Bubar of the Western District of Virginia said. “This historic resolution is the product of a continued partnership with the Virginia Medicaid Fraud Control Unit, FDA, HHS, and the U.S. Postal Service.”
    “This is a landmark moment in our fight to hold drug companies responsible for their role in the opioid crisis,” said Virginia Attorney General Mark Herring. “We will not allow anyone to put profits over people, or to exacerbate or exploit the opioid crisis for their own benefit. The Virginia Medicaid Fraud Control Unit’s expertise, capacity, and diligent investigation, combined with strong relationships with local, state, and federal partners, helped make this resolution possible.”
    “Opioid addiction and abuse is an immense public health crisis and taking steps to address it is one the FDA’s highest priorities,” said Acting FDA Commissioner Ned Sharpless, M.D. “Providing misleading information about product benefits puts the public at risk. We also are particularly concerned with schemes to game the drug approval process to prevent generic competition for important medicines. The FDA, including criminal investigators in our Office of Regulatory Affairs and the lawyers in our Office of Chief Counsel, will continue to work with the Department of Justice to investigate and hold accountable those who devise and participate in schemes to the detriment of the public health.”
    “The U.S. Postal Service spends billions of dollars per year in workers compensation-related costs, most of which are legitimate,” said Kenneth Cleevely, Special Agent in Charge of the Eastern Field Office for the U.S. Postal Service Office of Inspector General. “However, when medical providers or companies choose to flout the rules and profit illegally, special agents with the USPS OIG will work with our law enforcement partners to hold them responsible. To report fraud or other criminal activity involving the Postal Service, contact our special agents at www.uspsoig.gov or 888-USPS-OIG.”
    According to the indictment, Indivior—including during the time when it was a subsidiary of RB Group—promoted the film version of Suboxone (Suboxone Film) to physicians, pharmacists, Medicaid administrators, and others across the country as less-divertible and less-abusable and safer around children, families, and communities than other buprenorphine drugs, even though such claims have never been established.
    The indictment further alleges that Indivior touted its “Here to Help” internet and telephone program as a resource for opioid-addicted patients. Instead, however, Indivior used the program, in part, to connect patients to doctors it knew were prescribing Suboxone and other opioids to more patients than allowed by federal law, at high doses, and in a careless and clinically unwarranted manner.
    The indictment also alleges that, to further its scheme, Indivior announced a “discontinuance” of its tablet form of Suboxone based on supposed “concerns regarding pediatric exposure” to tablets, despite Indivior executives’ knowledge that the primary reason for the discontinuance was to delay the Food and Drug Administration’s approval of generic tablet forms of the drug.
    The indictment alleges Indivior’s scheme was highly successful, fraudulently converting thousands of opioid-addicted patients over to Suboxone Film and causing state Medicaid programs to expand and maintain coverage of Suboxone Film at substantial cost to the government.
    The Civil Settlement
    Under the civil settlement, RB Group has agreed to pay a total of $700 million to resolve claims that the marketing of Suboxone caused false claims to be submitted to government health care programs. The $700 million settlement amount includes $500 million to the federal government and up to $200 million to states that opt to participate in the agreement. The claims settled by the civil agreement are allegations only and there has been no determination of liability.
    The civil settlement addresses allegations by the United States that, from 2010 through 2014, RB Group directly or through its subsidiaries knowingly: (a) promoted the sale and use of Suboxone to physicians who were writing prescriptions without any counseling or psychosocial support and for uses that were unsafe, ineffective, and medically unnecessary and that were often diverted for uses that lacked a legitimate medical purpose; (b) promoted the sale or use of Suboxone Film to physicians and state Medicaid agencies using false and misleading claims that Suboxone Film was less susceptible to diversion and abuse than other buprenorphine products and that Suboxone Film was less susceptible to accidental pediatric exposure than tablets; and (c) submitted a petition to the Food and Drug Administration on Sept. 25, 2012, claiming that Suboxone Tablet had been discontinued “due to safety concerns” about the tablet formulation of the drug and took other steps to delay the entry of generic competition for Suboxone in order to improperly control pricing of Suboxone, including pricing to federal healthcare programs.
    “With the nation continuing to battle the opioid crisis, the availability of quality addiction treatment options is critical. When treatment medications are used, it is essential they be prescribed carefully, legally, and based on accurate information, to protect the health and safety of patients in federal healthcare programs,” said Gary L. Cantrell, Deputy Inspector General for Investigations at the U.S. Department of Health and Human Services. “Along with our federal and state law enforcement partners we will continue working to protect these vulnerable beneficiaries.”
    “Opioid manufacturers – like all drug manufacturers – have a duty to market their products both truthfully and safely,” said Craig Carpenito, U.S. Attorney for New Jersey. “Opioid manufacturers have an additional and critically important duty to maintain effective controls to prevent their highly dangerous products from being abused and diverted.”
    “The opioid crisis has caused devastation throughout the country, including in the lives of Federal employees, annuitants, and their families,” said Thomas W. South, Deputy Assistant Inspector General for Investigations for the Office of Personnel Management. “The OPM OIG is committed to working with the Department of Justice and our other law enforcement partners to combat this epidemic. As always, patient safety is our number one priority.”
    The civil settlement resolves the claims against RB Group in six lawsuits pending in federal court in the Western District of Virginia and the District of New Jersey under the qui tam, or whistleblower provisions of the False Claims Act, which allow private citizens to bring civil actions on behalf of the United States and share in any recovery.
    FTC Resolution
    Under a separate agreement with the Federal Trade Commission (FTC), RB Group has agreed to pay $50 million to resolve claims that it engaged in unfair methods of competition in violation of the Federal Trade Commission Act, 15 U.S.C. § 53(b). The FTC is filing a complaint in the United States District Court for the Western District of Virginia alleging anticompetitive activities by RB Group designed to impede competition from generic equivalents of Suboxone. RB Group no longer manufactures or markets drug products. As part of a consent decree, RB Group agreed that it would notify the FTC if it began marketing drug products in the United States. RB Group further agreed that if it filed a Citizen Petition with the FDA in connection with a drug product, it would simultaneously disclose to both the FDA and the FTC all studies and data relevant to that Citizen Petition. RB Group further agreed not to withdraw a drug from the market or otherwise disadvantage a drug after obtaining approval to market another drug containing the same active ingredient.
    “Buprenorphine products are approved for use in the treatment of Americans struggling to overcome opioid addiction, and, in the middle of the nation’s opioid crisis, RB Group allegedly sought to deny those consumers a lower-cost generic alternative to maintain its lucrative monopoly on the branded drug,” said Gail Levine, a Deputy Director of the FTC’s Bureau of Competition.
    A Multilateral Effort
    The criminal resolution with RB Group was handled by the U.S. Attorney’s Office for the Western District of Virginia and the Department of Justice’s Consumer Protection Branch based on an investigation by the Virginia Attorney General’s Medicaid Fraud Control Unit; FDA - Office of Criminal Investigation; United States Postal Service – Office of Inspector General; and Department of Health and Human Services - Office of Inspector General. The civil settlement was handled by the Civil Division’s Commercial Litigation Branch, the U.S. Attorney’s Office for the Western District of Virginia, and the U.S. Attorney’s Office for the District of New Jersey. Assistance was provided by representatives of the HHS Office of Counsel to the Inspector General; the HHS Office of the General Counsel, CMS Division; FDA’s Office of Chief Counsel; the U.S. Department of Agriculture Office of the General Counsel; the National Association of Medicaid Fraud Control Units; the Defense Criminal Investigative Service; the Office of Personnel Management - Office of Inspector General; the Department of Veterans’ Affairs Office of Inspector General; the Department of Labor - Office of Inspector General; and TRICARE Program Integrity.

    Voting is beautiful, be beautiful ~ vote.©

    Friday, May 31, 2019

    Cocktails & Popcorn: The Rape Of LARA - Michigan Business Regulatory Database Has An Invalid Hostname Moment

    Image result for the rape of lucretia
    The Rape of LARA by the rogues of the
    Michigan Office of Attorney General
    Earlier on Cocktails & Popcorn, Michigan Department of Licensing and Regulatory Affairs site went dark, then it went back up with a notice about an hour and half later that it was updating.

    Now, the last time I checked, when a government site is updating, it typically does not go dark.

    LARA went dark and was raped by the privateers who sailed in from their UCC Public Private Partnerships to pilfer our most precious treasures, the Children's Trust Funds.

    Image may contain: text
    A definite sign of hacking.

    I was having erotic fantasies that the feds had initiated Phase Six - Michigan goes into federal receivership, but thought it only best to bridal my lust and wait for a DOJ FBI Conjugal Collaborative presser.

    There was that moment of a fleeting thought that someone, somewhere, up in LARA was bleachbitting history, again, destroying federal evidence in those fake ass LLCs, NGOs and INCs they may, or may not have on file that took out federal mortgages from TARP, NSP2 and a myriad of other federal land and housing grant programs, but, alas, Bill *Smooches* Schuette is no longer Attorney General.

    Then, I began to wonder if Microsoft had some of those "occidental backdoors" intellectual property issues going on, which would mean they were hacked because it went dark and did not have the notice up until later.




    Oddly enough, it also crossed my mind that someone may have hired some of those *russian/israeli/ukrainian* Smarty Pants (The Global Collection) who sit in the Ivory Tower on the Hill to "ethically hack" LARA, but then I said, Meh. I will wait for the news because I know someone read my post.

    Behold, the beauty of the public record!

    I believe Dana is about to uncloak the Medicaid Fraud Control Unit and its deep, dark history in Michigan.

    Dana plays in the forest of The Celestial Goddess of the Woodshed, who watches from afar, to see if Dana is going to dig up the dead kids and the two boys who survived, to give their legacies proper honors and make them whole again, which shall never, ever happen, especially if you have died, came back, died again, came back, as she knows well of how this works, being in possession of the public record, and all.

    There is no monetary amount that can be assigned for justice to be served.

    I want to see Ricky Holland's entire family achieve justice, Dana.

    The over prescriptions are not just limited to opioids to adults, as children in foster care are the big pharmaceutical cash cow of Medicaid.

    Just look at the expenditures.

    I did.

    Ben did, too.

    I dedicate this to post in honor of My Sensei, Ben Hansen.

    Much love.

    #maytheheavensfall

    Michigan's top Medicaid doctor accused of over-prescribing opioids

    Dr. David Neff gives a presentation at a 2017 conference about tackling opioid addiction sponsored by Michigan State University's Institute
    David Neff
    The top doctor for Michigan's Medicaid program has been placed on paid administrative leave as state officials review allegations that he over-prescribed opioids to patients in his private practice.

    The state Department of Licensing and Regulatory Affairs filed a complaint with the Michigan Board of Osteopathic Medicine and Surgery on May 1, alleging that Dr. David Neff over-prescribed controlled substances to some patients in his part-time medical practice.

    The complaint accuses Dr. David Neff of failing to exercise due care, conform to minimal standards of practice or utilize the MAPS system. He also allegedly requested data for other than a legitimate medical purpose from the Michigan Automated Prescription System, which tracks all controlled substance prescriptions written in the state.

    On same day the complaint was filed, Neff was placed on leave from his $194,184-a-year position as Michigan's chief medical director for Medicaid, said Lynn Sutfin, spokesman for the Michigan Department of Health and Human Services.

    "Dr. Neff is on paid administrative leave as we await a resolution of the administrative complaint issued by LARA," Sutfin said in a Thursday email to The Detroit News.

    LARA investigators based the complaint on data from MAPS. They also reviewed the medical records Neff kept on 10 of his patients.

    A call Thursday to Neff's private practice office in Okemos was not answered.

    The complaint alleges that Neff prescribed higher doses of opioids to some patients than recommended by the U.S. Centers for Disease Control and Prevention. The federal agency urges doctors to limit most patients to no more than 50 morphine milligram equivalents per day for most patients or "avoid or carefully justify" doses of 90 MMEs or more. 

    Neff told LARA investigators that he currently treats about 85 patients in his part-time practice. He provides family medicine services to about 75 percent of them, but provides palliative care to the remaining 25 percent. Palliative care patients often have complex conditions or terminal illnesses that require higher-than-usual doses of controlled substances.

    One of his patients, Jane Doe 1, was on a "high MMEs" regimen "that fell below the standard of care for the patient's conditions," according to the complaint.

    A patient, Jane Doe 2, was prescribed 1,500 MMEs daily of Fentanyl patches.  The patches didn't adhere well, Neff said, so this patient would remove them before the full dose was used.

    In another case, Neff rapidly decreased Jane Doe 4's dose from 980 MMEs to 420 MMEs without adequately documenting a reason for the reduction, according to investigators.

    The complaint also alleges that Neff failed to run urine screens on any of the patients and failed to run MAPS reports on several patients, but ran three MAPS reports on Jane Doe 1 after she died.

    Michigan doctors have been required since June 1, 2018, to run MAPS reports before writing any prescription for more than a three-day supply of a controlled substance.

    Neff has 30 days to respond to the complaint from the date it was filed by LARA. He could seek a compliance conference where he could provide testimony and evidence to a LARA representative and a member of the Disciplinary Subcommittee of the state Board of Osteopathic Medicine and Surgery. Or he could request a hearing before a state administrative law judge.

    Punishments for the charges, if substantiated, are at the board's discretion and could range from a reprimand to probation, suspension or other sanctions.

    Voting is beautiful, be beautiful ~ vote.©

    Saturday, May 11, 2019

    Why Michigan Attorney Medicaid Fraud Control Unit Will Not Investigate Medicaid Fraud In Child Welfare - Wayne State University, MSU & Stealin'

    Did you arise from a sound slumber to wonder why the Michigan Attorney General refuses to investigation Medicaid fraud in child welfare?

    Probably not, but just in case you did, I have provided a lovely 1980's style industrial organizational instructional video, hailing from that wonderful period in history when everything was being programmed by that first, selected, generation of masses who were able to access institutions of higher learning and create your belief systems, represented by Zippy the Hippy.


    For those of you who did not take the time to watch the video, probably because you think you are know more than me, allow me to present a few more probabilities as to why the Michigan Attorney General will not investigate Medicaid fraud in child welfare:
    • Stealin';
    • Michigan is at the threshold on a federal ruling on the Michigan Child Welfare System in the court of Nancy Edmunds, who seems to be covering up Medicaid fraud;
    • Michigan Medicaid Fraud Control Unit is under federal investigation for covering up Medicaid fraud in child welfare;
    • My old qui tam is back open as an investigation because the Court just threw my case on a pile of desk paper dung mounds and completely just spat in my face when it came to basic due process because I had to call the court to remind them that they were supposed to at least follow the False Claims Act and issue an order to dismiss.  Considering that the Court totally violated the Act and my civil rights, the case was wiped from the docket so you cannot find it, but I have it on my Scribd somewhere if you would like to search;
    • Michigan Office of Attorney General is under international investigation for stuff, that I shall just leave it right there for everyone to speculate, unless you follow my reporting;
    • Dana does not have a freakin' clue of what is going on or what to do as it shall probably self-implicate herself; or,
    • #warcrimes
    I am going with all of the above.

    You know what they say,  "Gotta fund those campaigns!"

    State still considering Wayne State's request to investigate Medicaid payment program

    • Officials with Department of Health and Human Services are considering Wayne State's request to audit Medicaid program spending
    • WSU officials have said they have used program funds appropriately
    • University Pediatricians officials have charged that Wayne State has misused and possibly diverted nearly $61 million
    Officials from the Michigan Department of Health and Human Services are considering a request from Wayne State University to hire an outside expert to review the university medical school's handling of funds from a Medicaid program after questions about it were raised by several medical groups.

    Last month, Wayne State University President M. Roy Wilson, M.D., asked MDHHS to review its management of the 15-year-old Medicaid Public Entity Physician Payment Adjustment Program.

    The request was prompted after several clinical groups affiliated with Wayne State, led by University Pediatricians, charged the university could be skimming as much as $61 million from the estimated $150 million to $200 million in annual state funding, a charge the university denies.

    Under the program, Wayne State and six other "public entities" manage money for a program intended to pay physicians who treat Medicaid patients a higher rate to encourage their participation and expand access to care for Medicaid patients.

    Officials from MDHHS confirmed they received the request from Wayne State for the review. "We continue to work with them on the administration of the program. At this point, we are not sure it is necessary for the department to undertake a review, but would evaluate any analysis undertaken by a third party."

    After MDHHS issued that statement, Crain's received another email from a state spokesman saying that it is considering Wayne State's request to hire a third party. The spokesman said the state continues to work with WSU to resolve any issues.

    Two weeks ago, MDHHS told Crain's in an email that it is not the state's role to get involved with a dispute between a public entity and one of its subcontractors. Other public entities in Michigan include the University of Michigan and Michigan State University.

    "We, of course, would be happy to review the results of any independent audit of Wayne State University's administration of the PEPPAP program, should they choose to pursue such a formal review," a state spokesman said in an email.

    In mid-April, Wilson penned an email to pediatric faculty to explain the ongoing dispute with University Pediatricians and at least three other clinical groups over the university's use of PEPPAP funds.

    "Whether or not the Wayne State School of Medicine has the legal standing to keep part of the (Medicaid Public Entity Physician Payment Adjustment Program) funds to achieve the intent of the authorizing legislation is not a debatable question. It does," said Wilson in the email.

    "The question of whether the amount kept is appropriate or not is a related, yet different issue that should be addressed. It is important and cannot be adjudicated through the media," he said.

    Wilson then asked MDHHS to hire an independent "outside adjudicator of their choosing, expert in matters of PEPPAP funds, to review the School of Medicine's past and current practices with regard to these funds."

    Over the past two months, WSU has declined several requests from Crain's to account for the funds.

    Wayne officials insist they are managing the funds appropriately and according to state law. However, Crain's and several of the contracted clinical groups are asking the following questions.

    For example, how much does Wayne State receive each year through PEPPAP? Sources have estimated $150 million to $200 million, but that number has never been confirmed. How much of that goes to the contracted 23 clinical groups, including University Pediatricians? How much is retained in administrative fees and how much toward other projects to expand access to Medicaid patients?

    Based on the 6 percent administrative fee that Wayne State collects for the program, the annual amount of administrative fees could range from $9 million to $12 million. But it is not known how much more in PEPPAP funds are retained by Wayne State for other unspecified strategic initiatives.

    Wayne State said these initiatives include programs provide "access to specialty and sub-specialty providers for Medicaid patients and the impoverished populations in the City of Detroit."

    On April 5, Crain's reported that University Pediatricians questioned whether Wayne State has inappropriately retained $60.5 million in payments. Since then, three other of the 23 clinical groups under contract with Wayne State for enhanced Medicaid funding have questioned whether they also have been shortchanged.

    Wilson has defended Wayne State's use of the funds, saying every one of the 23 groups it contracts with has received "every penny ... due under this program." But WSU said the state has granted it great latitude in how it uses the funds.

    UP, which has dropped its formal affiliation with Wayne State and is having a running dispute with the university over a variety of other issues, is a 220-physician private medical group that serves DMC Children's Hospital of Michigan in Detroit. Some of its pediatrician members are on the faculty of Wayne State medical school.

    The Medicaid enhanced payment funding issue between UP and Wayne State came to a head last fall during bankruptcy proceedings of University Physician Group, a multispecialty faculty practice plan affiliated with the Wayne State University School of Medicine.

    Last November, UPG filed for bankruptcy protection after its three-year turnaround hit a wall and losses were starting to mount again, projected to exceed $10 million for 2018. WSU has been subsidizing UPG's losses the past 3 1/2 years.

    UP and other groups have asked in bankruptcy court proceedings for a full accounting of the PEPPAP funds. "We don't want excess money used to create an entity by Wayne State that is in competition with UP" or to subsidize losses at the medical school or UPG, said a pediatrician source, who asked to remain anonymous.

    The UP source said the pediatrics group is concerned Wayne State plans to use about $25 million in PEPPAP funds to build a new pediatric clinic that would compete with UP for patients.

    Last month, WSU announced a plan to form Wayne Pediatrics, a new clinical service group of the university's medical school that is intended to replace longtime partner University Pediatricians. The decision was in response to UP's decision to terminate its relationship with Wayne State.

    Voting is beautiful, be beautiful ~ vote.©

    Thursday, January 31, 2019

    DMC Joins Detroit Funeral Homes In Warehousing Hundreds Of Fetuses

    I have so many questions, starting with the Medicaid billing for the births, but you know the Michigan Department of Health & Human Services does not like to give up records and the Michigan Medicaid Fraud Control Unit is useless.

    That is where you start, with the records, because you know someone was making money.

    Where are the identities, now?

    I would be extremely curios to find out the forensic condition of the fetuses, just to take an organ inventory and cause of death, because Detroit is #1 in the world for a geographic population in infant mortality and #1 in the world for parenatal research.

    It would be horrible to allege these global milestones in Detroit are found to harken from involuntary human subject research.

    Police remove 26 fetuses from Detroit Medical Center

    Detroit — In the latest twist to a wide-ranging investigation into funeral homes' disposition of infant and fetal remains, a police task force Monday removed 26 fetuses from a Detroit Medical Center morgue, all of which were allegedly mishandled by Perry Funeral Home.

    Members of the Detroit police homicide task force executed a search warrant Monday at Detroit Receiving Hospital, where the DMC's morgue is located, Detroit police Chief James Craig said.

    "This is a continuation into our criminal investigation into Perry Funeral Home," Craig said. "We removed 26 fetuses from the DMC."

    Craig added: "DMC was not a target of this action."

    DMC spokeswoman Tonita Cheatham said in an email: "We are working closely with local law enforcement in their ongoing investigation of Perry Funeral Home. The DMC has assisted law enforcement with the transfer of the unburied, Perry-related remains into their custody.”

    Perry spokesman Tom Shields said Tuesday he would ask the funeral home's attorneys to comment, but he did not provide a response.

    Twenty of the bodies taken from the DMC cooler had dates-of-birth listed from 1998 and earlier, with six dating to the 1970s, police sources told The Detroit News. The earliest date of birth accompanying a fetus was Aug. 11, 1971.

    Investigators are trying to determine whether those dates represent the infants' or parents' dates of birth, sources said. Perry has contracted with area hospitals to handle unclaimed infant and fetal remains since at least the 1960s.

    Only partial information was available about some remains because the bodies were decomposed, and identifying paperwork was either missing or too soiled to be legible, sources told The News.
    Meanwhile, state authorities are looking into another case of dozens of infant remains allegedly lying unnoticed for years in a DMC hospital.

    LARA since October has been investigating a tip from a former Harper-Hutzel Hospital employee that hospital officials in April 2015 found the dead bodies of more than 50 infants in a basement morgue.

    The former hospital employee told The News and officials with the Michigan Department of Licensing and Regulatory Affairs that at least 20 of the babies had identification tags indicating they had been in the hospital morgue for more than 10 years.

    LARA spokesman Jason Moon said Tuesday the state agency is investigating the former employee's claims.

    "LARA received an anonymous complaint regarding the allegations ... and we are discussing it with law enforcement to determine whether our department has regulatory oversight over the issues addressed by the complainant," Moon said.

    Cheatham did not respond to questions about the former employee's allegations.
    LARA was not involved in Monday's search warrant, Moon said.

    The 26 remains removed from the DMC morgue Monday were taken to a mortuary transport company.

    One fetus among the 26 is listed as “Mary Doe” because there’s no identifying information about her, according to sources.

    Sources said Perry removed the remains from the hospital at some point, then returned them, and investigators are trying to figure out why. Paperwork at the morgue indicated Perry brought the remains back to the DMC morgue on July 28, 2017, sources told The News.

    Monday's action was the latest development in a multi-tentacled investigation into the handling of infant and fetal remains.

    The probe started in October, when Detroit police and LARA inspectors discovered 11 infant and fetal remains stored in a false ceiling at Detroit's Cantrell Funeral Home, after receiving a letter that also alleged fraud at the funeral home.

    Craig said he launched the investigation because failing to properly dispose of remains more than 180 days after death is a felony in Michigan, punishable by up to 10 years in prison.

    When a man who was suing Perry and others for allegedly mishandling his daughter's remains saw news coverage of the Cantrell discovery, his attorneys alerted Detroit police. Police met with the attorneys and then expanded their investigation to include Perry Funeral Home.

    The lawsuit being handled by the attorneys, Peter Parks and Daniel Cieslak, was granted class-action status in November after the lawyers argued there could be more than 200 mishandled remains.

    The parents involved in the lawsuit had arranged for the remains of their stillborn or live-birth babies to go to Wayne State's medical school for research. Instead, the lawsuit alleges, many of the bodies ended up in Wayne State's morgue, which had a longstanding arrangement allowing Perry Funeral Home to store bodies in its cooler.

    In June 2017, the university told Perry to remove the remains stored in the cooler because there wasn't enough room, and the remains were taken back to the funeral home.

    On Oct. 19, Detroit police and LARA raided Perry and removed 63 fetuses, 36 of which were stored in an unrefrigerated box. Following the raid, LARA shut down Perry and suspended the mortuary science licenses of the funeral home and its director, Gary Deak.

    In December, LARA moved to permanently revoke Cantrell's license, after state officials said they found "numerous acts of fraud, deceit, dishonesty, incompetence and gross negligence."

    The alleged violations included reusing caskets, and knowingly making false statements on death certificates.

    Knollwood Park Cemetery in Canton Township is also part of the investigation, which is being handled by a multi-jurisdictional task force involving Detroit police, Michigan State Police, the FBI, LARA and the Michigan Attorney General's Office.

    In December, LARA officials halted all new activity at the cemetery, after inspectors found more than 300 improperly-stored infant and fetal remains in multiple crypts.

    Voting is beautiful, be beautiful ~ vote.©